1. Home
  2. ALLE vs VTRS Comparison

ALLE vs VTRS Comparison

Compare ALLE & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allegion plc

ALLE

Allegion plc

HOLD

Current Price

$165.87

Market Cap

13.9B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$10.69

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLE
VTRS
Founded
2013
1961
Country
Ireland
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
12.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ALLE
VTRS
Price
$165.87
$10.69
Analyst Decision
Hold
Hold
Analyst Count
9
6
Target Price
$172.22
$11.17
AVG Volume (30 Days)
731.2K
9.1M
Earning Date
10-23-2025
11-06-2025
Dividend Yield
1.24%
4.49%
EPS Growth
13.70
N/A
EPS
7.39
N/A
Revenue
$3,979,700,000.00
$14,124,400,000.00
Revenue This Year
$10.07
N/A
Revenue Next Year
$6.55
$1.61
P/E Ratio
$22.35
N/A
Revenue Growth
6.87
N/A
52 Week Low
$116.57
$6.85
52 Week High
$180.68
$13.25

Technical Indicators

Market Signals
Indicator
ALLE
VTRS
Relative Strength Index (RSI) 49.10 55.18
Support Level $158.74 $10.49
Resistance Level $167.26 $10.73
Average True Range (ATR) 3.09 0.31
MACD 0.72 -0.01
Stochastic Oscillator 65.02 47.35

Price Performance

Historical Comparison
ALLE
VTRS

About ALLE Allegion plc

Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: